When do treat donovo DSA without histological ABMR in renal transplantation
Reading File
De novo donor-specific antibodies (dnDSA) without histological ABMR is a recognized clinical dilemma - treatment is generally indicated when there are risk factors for progression (high MFI, complement-fixing C1q/C3d-binding, rising DSA, functional decline), but observation may be appropriate in low-risk cases.
Searching sources...
Finding Sources
Searching PubMed
de novo donor specific antibody renal transplant treatment without ABMR
Finding Sources
Searching PubMed
de novo DSA kidney transplant subclinical treatment
Finding Sources
Searching PubMed
dnDSA kidney transplant management ABMR histology
Finding Sources
Searching PubMed
"de novo donor-specific antibodies" kidney transplant treatment subclinical
Finding Sources
Reading Article
PMID: 37169835
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.